MiYOSMART iQ: Advancing Childhood Myopia Care

Introduction: Why Myopia Management Requires a More Advanced Clinical Approach

Childhood myopia management has become an increasingly important area of focus for Eye Care Professionals. The clinical approach has evolved from simply correcting refractive error to proactively managing myopia progression through early detection, evidence-based interventions, and continuous monitoring.

For years, spectacle lenses have primarily corrected vision by providing clear sight. However, progressive myopia requires a broader clinical strategy that considers the factors influencing ocular growth and refractive development.

Today, ECPs are increasingly adopting myopia management approaches that combine optical innovation, clinical evidence, and patient-specific decision-making. This shift has created the need for solutions that not only support clear vision but also provide a targeted optical approach for managing myopia progression.

Building on the established foundation of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology, HOYA introduces MiYOSMART iQ, an advanced myopia control spectacle lens incorporating Triple Enhanced Design (DIMS TED) to further refine the delivery of myopic defocus signals.


What is MiYOSMART iQ and how does it support myopia management?

MiYOSMART iQ is HOYA’s latest advancement in spectacle lens-based myopia management. It combines the clinically established D.I.M.S. Technology platform with a new Triple Enhanced Design that improves the treatment zone's optical configuration.

The lens is designed around two functional zones:

  • Clear Vision Zone: Provides central visual correction for daily activities.
  • Treatment Zone: Incorporates multiple defocus segments that deliver myopic defocus signals while maintaining clear vision.

This dual-zone approach lets ECPs address two key clinical requirements at once: functional vision correction and myopia management support.


How does Triple Enhanced Design improve the D.I.M.S. Technology platform?

The advancement of MiYOSMART iQ lies in its Triple Enhanced Design, which introduces three key improvements to the D.I.M.S. optical configuration:

1. Activated Design: Optimizing Defocus Segment Position

MiYOSMART iQ positions defocus segments closer to the spectacle lens's geometric center.

Clinically, this design aims to maintain continuous activation of the near-peripheral retina, an area identified as responsive to myopic defocus signals.

The defocus segments are positioned to deliver a more consistent optical signal under natural viewing conditions, supporting the mechanism behind myopia management.

2. Powerful Design: Delivering a Stronger Myopic Defocus Signal

The second enhancement increases the defocus power within the treatment zone.

A stronger myopic defocus signal is designed to provide an enhanced optical stimulus to the near-peripheral retina while maintaining central visual clarity.

For ECPs, understanding the relationship between optical design and clinical outcomes is essential when selecting appropriate myopia management solutions for children.

3. Extended Design: Expanding Treatment Zone Coverage

Children have different facial structures, frame preferences, and visual behaviors. Therefore, treatment zone coverage and frame compatibility are important practical considerations.

MiYOSMART iQ incorporates an extended treatment zone designed to provide wider peripheral coverage of myopic defocus signals, supporting a broader range of children’s spectacle frames.


What clinical evidence supports MiYOSMART iQ?

Clinical evidence helps guide myopia management decisions. A randomized controlled clinical trial evaluated MiYOSMART iQ in children aged 4 to 12 years.

The reported clinical outcomes showed:

  • 9 out of 10 children showed no clinically relevant myopia progression during the first 12 months of wear.
  • MiYOSMART iQ represents HOYA’s first spectacle lens with reported clinical evidence for controlling myopia progression from age 4 years as a monotherapy.

These findings build on the broader D.I.M.S. Technology platform, which is supported by more than 100 peer-reviewed publications and long-term research experience.

More broadly, HOYA’s MiYOSMART platform is supported by extensive clinical research and global adoption in childhood myopia management, which gives ECPs a well-established reference point when evaluating spectacle lens options for their pediatric patients.

For ECPs, this evidence provides a foundation for discussing spectacle lens-based myopia management options with suitable pediatric patients.

Why Early Intervention Matters

Early identification and intervention are important because younger children typically face a greater risk of faster myopia progression. When myopia begins earlier, there is more time for refractive error to increase through childhood, which is why age of onset is a key factor ECPs consider during assessment.

This is also why clinical evidence in younger children is relevant. With MiYOSMART iQ evaluated in children from age 4 years, ECPs have a basis for starting myopia management conversations early rather than waiting for significant progression to occur. Combined with regular follow-up, early intervention allows ECPs to respond to changes in a child’s myopia as they happen.


How can Eye Care Professionals integrate MiYOSMART iQ into clinical practice?

Successful myopia management requires more than prescribing a lens. It involves patient assessment, accurate fitting, patient education, and ongoing monitoring.

Patient Assessment

The first step is identifying children who may benefit from myopia management.

ECPs should consider:

  • Age of myopia onset
  • Rate of refractive progression
  • Previous management history
  • Visual requirements
  • Lifestyle factors

MiYOSMART iQ has been evaluated in children with progressing myopia from age 4 years, with suitability determined through professional clinical judgment.

Precision Fitting and Centration

Accurate fitting is essential for spectacle lens-based myopia management because the treatment zone must align appropriately with the wearer’s visual system.

HOYA supports ECPs through tools such as the visuReal MoveAI Kids Module, an AI-powered centration tool developed specifically for pediatric myopia management lenses.

Proper frame selection and centration help ensure that the optical design performs as intended.

Follow-Up and Monitoring

Myopia management is a long-term clinical process, not a one-time prescription decision.

Regular follow-up allows ECPs to evaluate:

  • Changes in refractive error
  • Axial length progression
  • Treatment compliance
  • Patient adaptation

HOYA recommends follow-up within six months, including monitoring axial length and myopia progression where appropriate.


How does MiYOSMART iQ support visual comfort and compliance?

For pediatric patients, long-term success depends not only on treatment performance but also on consistent spectacle wear.

MiYOSMART iQ incorporates FreeForm Technology, which uses advanced calculations to optimize the backside lens design, improve optical accuracy, reduce optical aberrations, and create a thinner lens profile.

The design supports:

  • Clearer vision across different gaze positions
  • Improved optical performance
  • Enhanced lens aesthetics
  • Better frame compatibility

The optimized design can reduce edge thickness by up to 10% compared with standard spectacle lenses.


What is S.P.A.R.K. Coating and why is it important for children?

Children’s eyewear must withstand everyday activities while maintaining optical performance.

MiYOSMART iQ features S.P.A.R.K. Coating, a protective coating designed specifically for children’s spectacle lenses.

The coating provides:

  • Enhanced scratch resistance
  • Resistance against smudges, dust, and water
  • Easy cleaning performance
  • UV protection
  • Reduced glare and reflections

These features help improve durability and support consistent wear throughout childhood.

Conclusion: Supporting the Next Generation of Myopia Management

Managing childhood myopia requires a balance of clinical evidence, optical technology, and practitioner expertise.

MiYOSMART iQ represents the next step in spectacle lens-based myopia management by combining the established foundation of D.I.M.S. Technology with Triple Enhanced Design, advanced optical optimization, and ECP-focused clinical support.

For Eye Care Professionals, MiYOSMART iQ provides an opportunity to move beyond traditional refractive correction and adopt a more comprehensive approach to managing childhood myopia through assessment, precision fitting, and continuous monitoring.